{
    "clinical_study": {
        "@rank": "120837", 
        "arm_group": {
            "arm_group_label": "Lu AA21004", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The rationale for this pharmacokinetic (PK) study is to determine the PK parameters for Lu\n      AA21004 (Vortioxetine) in the Chinese population."
        }, 
        "brief_title": "Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject is a Chinese man or woman\n\n          -  The subject is, in the opinion of the investigator, generally healthy\n\n          -  If female, the subject must have a negative pregnancy test at screening and baseline,\n             and agree not to try to become pregnant from Screening until after the Follow-up\n             Visit\n\n        Exclusion Criteria:\n\n          -  The subject is, in the opinion of the investigator, unlikely to comply with the\n             clinical study protocol or is unsuitable for any other reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676571", 
            "org_study_id": "14077A"
        }, 
        "intervention": {
            "arm_group_label": "Lu AA21004", 
            "description": "10 mg immediate-release (IR), one single dose, orally", 
            "intervention_name": "Lu AA21004", 
            "intervention_type": "Drug", 
            "other_name": "Vortioxetine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "zip": "300457"
                }, 
                "name": "CN001"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-centre, Open-label, Single-dose Interventional Study Investigating the Pharmacokinetic Properties of Lu AA21004 in Healthy Young Chinese Men and Women", 
        "other_outcome": [
            {
                "description": "Metabolic ratio (MR)", 
                "measure": "PK MR determination of metabolites Lu AA34443 and Lu AA39835", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "measure": "Number of patients with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "11 days"
            }
        ], 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the curve (AUC)", 
                "measure": "PK AUC determination of Lu AA21004 (Vortioxetine)", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }, 
            {
                "description": "Maximum observed concentration (Cmax)", 
                "measure": "PK Cmax determination of Lu AA21004 (Vortioxetine)", 
                "safety_issue": "No", 
                "time_frame": "11 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676571"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}